Repligen Corporation (RGEN) Shares Bought by BlackRock Inc.

BlackRock Inc. boosted its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 143,196.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,664,302 shares of the biotechnology company’s stock after buying an additional 4,661,047 shares during the period. BlackRock Inc. owned about 13.78% of Repligen Corporation worth $164,187,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. TimesSquare Capital Management LLC boosted its position in Repligen Corporation by 35.1% in the first quarter. TimesSquare Capital Management LLC now owns 1,970,725 shares of the biotechnology company’s stock valued at $69,370,000 after buying an additional 512,300 shares in the last quarter. Norges Bank acquired a new position in Repligen Corporation during the fourth quarter valued at $8,527,000. Macquarie Group Ltd. boosted its position in Repligen Corporation by 481.1% in the fourth quarter. Macquarie Group Ltd. now owns 319,668 shares of the biotechnology company’s stock valued at $9,852,000 after buying an additional 264,659 shares in the last quarter. MARSHALL WACE ASIA Ltd acquired a new position in Repligen Corporation during the first quarter valued at $9,006,000. Finally, Marshall Wace North America L.P. acquired a new position in Repligen Corporation during the first quarter valued at $9,006,000. Institutional investors own 99.02% of the company’s stock.

Repligen Corporation (NASDAQ RGEN) opened at 42.71 on Thursday. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of 112.69 and a beta of 1.30. The company’s 50-day moving average price is $41.28 and its 200-day moving average price is $36.10. Repligen Corporation has a 52 week low of $26.16 and a 52 week high of $46.81.

Repligen Corporation (NASDAQ:RGEN) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The firm had revenue of $32.40 million for the quarter, compared to analyst estimates of $31.72 million. During the same quarter last year, the business earned $0.16 earnings per share. Repligen Corporation’s revenue was up 11.0% compared to the same quarter last year. Equities analysts forecast that Repligen Corporation will post $0.58 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/08/10/repligen-corporation-rgen-shares-bought-by-blackrock-inc-updated-updated.html.

A number of analysts recently commented on RGEN shares. First Analysis reiterated an “equal weight” rating and set a $40.00 price objective on shares of Repligen Corporation in a research report on Friday, April 21st. BidaskClub cut Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 14th. Jefferies Group LLC reissued a “hold” rating and set a $40.00 price target (up previously from $33.00) on shares of Repligen Corporation in a report on Wednesday, June 28th. William Blair started coverage on Repligen Corporation in a report on Friday, July 21st. They set an “outperform” rating for the company. Finally, Zacks Investment Research lowered Repligen Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Repligen Corporation presently has an average rating of “Buy” and an average price target of $41.20.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply